October 23rd 2019
Daniel J. George, MD, discusses the changing treatment landscape in prostate cancer.
October 17th 2019
Daniel J. George, MD, discusses investigational agents downstream of the androgen receptor in advanced prostate cancer.
September 18th 2019
Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the use of radium-223 dichloride (Xofigo) in prostate cancer.
August 9th 2019
Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses the promise of PARP inhibitors in prostate cancer.
April 10th 2019
Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses next steps for research in renal cell carcinoma (RCC).
April 3rd 2019
Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the impact of immunotherapy on TKIs in renal cell carcinoma (RCC).
March 20th 2019
Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses the importance of dosing TKIs properly in patients with renal cell carcinoma (RCC).
February 15th 2019
Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses sequential therapy in metastatic prostate cancer.
January 10th 2019
Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses concerns with immune-related adverse events (irAEs) in renal cell carcinoma (RCC).
December 18th 2018
Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses sequencing in renal cell carcinoma (RCC).